SCHEMBL8905655

SCHEMBL8905655

COc1cccc(Cc2nc(Nc3ccc(-n4ccnc4C)cc3)nc3c2CN(C(=O)OC(C)(C)C)CC3)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 2/20 0.49
MKNK1 Q9BUB5 1/20 0.41
P2RX3 P56373 1/20 0.40
KDR P35968 2/20 0.38
C5AR1 P21730 4/20 0.38
ROCK2 O75116 2/20 0.37
PDE10A Q9Y233 1/20 0.37
JAK2 O60674 2/20 0.37
JAK3 P52333 2/20 0.37
PTK2 Q05397 2/20 0.37
PDGFRB P09619 1/20 0.36
STAT6 P42226 1/20 0.36
CDK4 P11802 1/20 0.35
CCND1 P24385 1/20 0.35
CCND2 P30279 1/20 0.35
CCND3 P30281 1/20 0.35
CCNT1 O60563 1/20 0.35
CCNA2 P20248 1/20 0.35
CDK2 P24941 1/20 0.35
CDK9 P50750 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2451842 0.91 CREBBP (0.41) MAPTKDRROCK2JAK2PTK2
SCHEMBL2483114 0.91 KDR (0.40) MAPTKDRROCK2JAK2PTK2
SCHEMBL2839484 0.91 MAPT (0.46) MAPTP2RX3C5AR1ROCK2PDE10A
SCHEMBL8905497 0.88 MAPT (0.46) MAPTMKNK1C5AR1PDE10AJAK2
SCHEMBL2447174 0.86 ROCK2 (0.43) MAPTKDRROCK2JAK2PTK2
SCHEMBL8905533 0.85 MAPT (0.44) MAPTMKNK1KDRC5AR1ROCK2
SCHEMBL2450286 0.84 MAPT (0.43) MAPTP2RX3C5AR1PDE10AJAK2
SCHEMBL2482423 0.84 MAPT (0.40) MAPTKDRROCK2JAK2PTK2
SCHEMBL8904410 0.83 MAPT (0.47) MAPTMKNK1C5AR1PDE10AJAK2
SCHEMBL2842254 0.82 MAPT (0.51) MAPTMKNK1C5AR1PDE10AJAK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-8188101-B2 Dihydropyridopyrimidines for the treatment of AB-related pathologies ASTRAZENECA AB (SE) 2012-05-29 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
US-20100130495-A1 COMPOUNDS 563 ASTRAZENECA AB (SE) 2010-05-27 US disclosed
WO-2010053438-A1 MODULATORS OF AMYLOID BETA. ASTRAZENECA AB (SE) 2010-05-14 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100130495-A1 COMPOUNDS 563 BACE1, PSEN1, PSEN2 MAPT 10/4885MKNK1 653/4885P2RX3 2295/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.